John Cochrane on the Pandemic

Episode Summary

Executive Summary: Russ Roberts and John Cochrane argue that COVID policy repeatedly failed by treating testing, vaccines, masks, and distribution as bureaucratic problems instead of market-and-incentive problems. Cochrane contends that freer pricing, faster approvals, voluntary testing/isolation, and market-based logistics would have accelerated containment, expanded supply, and reduced damage while still allowing government to target subsidies and protection for the vulnerable.

Main Topics: Testing as a missed opportunity (Priority: 5/5): Cochrane says the CDC and FDA slowed testing by blocking private and university alternatives, favoring over-precise clinical standards instead of fast, cheap, at-home tests that could have enabled voluntary isolation and reduced spread. Vaccines, approval, and challenge trials (Priority: 5/5): The discussion praises mRNA vaccine science but criticizes the FDA's cautious, slow approval process and rejection of challenge trials; Cochrane argues faster, broader access could have shortened the pandemic. Pricing, rationing, and vaccine distribution (Priority: 5/5): They debate whether vaccines should have been sold at market prices on top of government subsidies. Cochrane argues price signals would have improved allocation, incentivized production, and let employers or schools secure doses quickly. Lockdowns versus smart reopening (Priority: 4/5): Cochrane criticizes broad lockdowns as economically costly and often misdirected, favoring targeted public-health rules aimed at superspreading settings rather than blanket shutdowns. Shortages, price gouging, and the role of markets (Priority: 4/5): The conversation uses toilet paper, masks, gas, and hotel rooms to explain why price controls create shortages and hoarding, while higher prices help allocate scarce goods and induce more supply. Bureaucracy, data, and public-health state capacity (Priority: 4/5): Both speakers emphasize the need for better random testing, sequencing, logistics, and data collection; Cochrane says governments lacked the bureaucratic competence and information-gathering needed for a fast-moving pandemic. Global responsibility and China (Priority: 3/5): The final segment raises questions about China’s role in the pandemic origin and the difficulty of holding it accountable, while Cochrane stresses the need for competent global public-health institutions.

Key Arguments: Private and university testing was blocked early, delaying the ability to test, trace, and voluntarily isolate before exponential spread took hold. The FDA’s mentality is shaped by rare-drug safety disasters like thalidomide, making it too slow for a pandemic where speed matters more than perfect individual-level accuracy. Challenge trials and earlier voluntary vaccine access could have generated efficacy data faster, potentially shortening the pandemic by months. Vaccines are not only individual protection; they are tools for reducing transmission, so distribution should prioritize those whose vaccination most lowers spread and enables economic reopening. A market price for vaccines would not be immoral; it would allocate scarce doses efficiently, encourage production, and let employers and individuals make tradeoffs about staying home versus paying for access. Government rationing focused on age and bureaucracy rather than transmission effects, delaying reopening and ignoring higher-value uses such as teachers, prisoners, and workers in contact-intensive jobs. Broad lockdowns were too blunt and often targeted low-risk activities while missing settings where superspreading actually occurs. Price controls or anti-gouging rhetoric on masks, toilet paper, gas, and other goods reduced incentives to produce and ship scarce items, worsening shortages. The state should focus on buying/supplying vaccines and protecting vulnerable groups, but allow market forces on top to speed production, distribution, and innovation. Random sampling, sequencing, and transparent data collection should be central tools for future pandemic policy, because the existing test data mainly reflected symptomatic people seeking tests.

Data Points: Podcast date: January 26, 2021 - Episode date given in the introduction Cochrane appearance on EconTalk: 6th appearance - Russ Roberts notes this is John Cochrane's sixth appearance Testing delay: 1-2 months behind schedule - Cochrane says CDC errors and bans delayed testing At-home test price estimate: $2-$5 - Cochrane proposes cheap paper-strip home tests FDA-priced test example: $50 plus doctor prescription and app enrollment - Describes the only test finally allowed after long delay False positive/negative example: 1 in 10 - Used to argue that imperfect rapid tests could still suppress spread Vaccine development time: 2 days of lab time - Cochrane says the vaccine’s design took only days once the genetic code was known Vaccine approval timeline: 11 months - He calls development-to-approval a record but still too slow U.S. vaccination rate cited: about 6-7% - Roberts cites U.S. rollout progress at end of January 2021 UK vaccination rate cited: about 10% - Roberts compares rollout internationally Israel vaccination rate cited: 44% - Roberts says Israel was the leading vaccinator at the time Government vaccine advance spending: $4-$5 billion - Advanced purchase/subsidy to incentivize production under Operation Warp Speed Pandemic spending: $5 trillion - Used to argue that vaccine and supply incentives are trivial by comparison Hotel room example: $450 per night - Cochrane’s anecdote about surge pricing during Woodstock California fine example: $20,000 - Fine for leaving hotel quarantine room in Australia, used in comparison to U.S. isolation politics Supervision/logistics example: 20-person minutes - Time per vaccine delivery largely due to paperwork and logistics Israel population: about 9 million - Explains why Israeli HMOs could organize vaccination efficiently

Pivotal Quotes: "The market is very much a second best, the worst of all possible systems, except for all of the others, as the saying goes." — John Cochrane: Opening framing of his position: not pure laissez-faire, but markets layered on top of government "We needed to slow down the spread. And the one thing you have to get in mind about these diseases is how nonlinear it is." — John Cochrane: Explaining why cheap, rapid testing and voluntary isolation matter more than perfect bureaucratic control "Let the price system work, transfer incomes." — John Cochrane: His bottom-line argument on vaccines, shortages, and resource allocation

Implications: Listeners are left with a strong case for pandemic policy that prizes speed, incentives, and targeted public health over centralized control. Future responses should expand testing, data, and vaccine access quickly while letting prices and private logistics help allocate scarce resources.